iwAL 2026 | Sequencing targeted therapies in AML with multiple targetable alterations
Amir Fathi
• 21 Sep 2026
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses uncertainties around sequencing targeted therapies in acute myeloid leukemia (AML). He highlights the lack of definitive evidence to guide treatment for patients with multiple targetable alterations and discusses emerging trials evaluating combinations of menin and FLT3 inhibitors. This interview took place at the 8th International Workshop on Acute Leukemias (iwAL 2026), held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
